ZN-d5-001
08 Jun 2021
ZN-d5-001
NCT04500587
Phase 1 First in Human Dose-Escalation Study of ZN-d5 as a Single Agent in Subjects With Non-Hodgkin Lymphoma or Acute Myeloid Leukemia
K-Group Alpha, Inc.
Cancer Type | Non-Hodgkin Lymphoma; Acute Myeloid Leukemia |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | - |
Anticipated Start Date | 2020-10-13 |
Anticipated End Date | 2023-05-01 |
Hospital | Icon Cancer Centre Adelaide |
---|---|
Clinical Trial Coordinator | Sue Yeend |
sue.yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Dr Akash Kalro |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs